Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm*, Nigel Armstrong, Bram L. T. Ramaekers, Xavier Pouwels, Shona Lang, Svenja Petersohn, Rob Riemsma, Gillian Worthy, Lisa Stirk, Janine Ross, Jos Kleijnen, Manuela A. Joore

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)655-667
Number of pages13
JournalPharmacoeconomics
Volume37
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • PHASE-III TRIAL
  • WEEKLY PACLITAXEL
  • VINFLUNINE PLUS
  • SUPPORTIVE CARE
  • OPEN-LABEL
  • CARCINOMA
  • MONOTHERAPY
  • MULTICENTER
  • DOCETAXEL

Cite this

@article{3bc576bbf4d54c149801df0163bbee76,
title = "Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",
keywords = "PHASE-III TRIAL, WEEKLY PACLITAXEL, VINFLUNINE PLUS, SUPPORTIVE CARE, OPEN-LABEL, CARCINOMA, MONOTHERAPY, MULTICENTER, DOCETAXEL",
author = "Grimm, {Sabine E.} and Nigel Armstrong and Ramaekers, {Bram L. T.} and Xavier Pouwels and Shona Lang and Svenja Petersohn and Rob Riemsma and Gillian Worthy and Lisa Stirk and Janine Ross and Jos Kleijnen and Joore, {Manuela A.}",
year = "2019",
month = "5",
doi = "10.1007/s40273-018-0723-5",
language = "English",
volume = "37",
pages = "655--667",
journal = "Pharmacoeconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "5",

}

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Grimm, Sabine E.; Armstrong, Nigel; Ramaekers, Bram L. T.; Pouwels, Xavier; Lang, Shona; Petersohn, Svenja; Riemsma, Rob; Worthy, Gillian; Stirk, Lisa; Ross, Janine; Kleijnen, Jos; Joore, Manuela A.

In: Pharmacoeconomics, Vol. 37, No. 5, 05.2019, p. 655-667.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer

T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Grimm, Sabine E.

AU - Armstrong, Nigel

AU - Ramaekers, Bram L. T.

AU - Pouwels, Xavier

AU - Lang, Shona

AU - Petersohn, Svenja

AU - Riemsma, Rob

AU - Worthy, Gillian

AU - Stirk, Lisa

AU - Ross, Janine

AU - Kleijnen, Jos

AU - Joore, Manuela A.

PY - 2019/5

Y1 - 2019/5

KW - PHASE-III TRIAL

KW - WEEKLY PACLITAXEL

KW - VINFLUNINE PLUS

KW - SUPPORTIVE CARE

KW - OPEN-LABEL

KW - CARCINOMA

KW - MONOTHERAPY

KW - MULTICENTER

KW - DOCETAXEL

U2 - 10.1007/s40273-018-0723-5

DO - 10.1007/s40273-018-0723-5

M3 - Review article

VL - 37

SP - 655

EP - 667

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 5

ER -